Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec 30:10:55-63.
doi: 10.2147/OPTH.S80489. eCollection 2016.

Anxiety and depression in patients with advanced macular degeneration: current perspectives

Verena R Cimarolli  1 , Robin J Casten  2 , Barry W Rovner  3 , Vera Heyl  4 , Silvia Sörensen  5 , Amy Horowitz  6
Affiliations
Review

Anxiety and depression in patients with advanced macular degeneration: current perspectives

Verena R Cimarolli et al. Clin Ophthalmol. .

Abstract

Age-related macular degeneration (AMD) - despite advances in prevention and medical treatment options - remains prevalent among older adults, often resulting in functional losses that negatively affect the mental health of older adults. In particular, the prevalence of both anxiety and depression in patients with AMD is high. Along with medical treatment options, low vision rehabilitation and AMD-specific behavioral and self-management programs have been developed and have demonstrated effectiveness in improving the mental health of AMD patients. This article reviews the prevalence of anxiety and depression in patients with advanced AMD, discusses potential mechanisms accounting for the development of depression and anxiety in AMD patients, presents the state-of the-art of available interventions for addressing anxiety and depression in AMD patients, and delineates recommendations for eye care professionals regarding how to screen for these two prevalent mental health problems and how to facilitate appropriate treatment for patients with AMD.

Keywords: age-related macular degeneration; anxiety; behavioral and self-management interventions; depression; vision impairment; vision rehabilitation.

PubMed Disclaimer

References

    1. World Health Organization . Global data on visual impairments 2010. World Health Organization; 2012. [Accessed November 9, 2015]. Available from: http://www.who.int/blindness/GLOBALDATAFINALforweb.pdf.
    1. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–e116. - PubMed
    1. Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564–572. - PubMed
    1. Klein R, Chou CF, Klein BE, Zhang X, Meuer SM, Saaddine JB. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol. 2011;129(1):75–80. - PubMed
    1. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol. 1988;32(6):375–413. - PubMed